BRISTOL-MYERS SQUIBB COMPANY Long-Term Debt, Maturity, after Year Five
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Long-Term Debt, Maturity, after Year Five of $5.50 billion as of 2013-12-31, per its 10-K filed 2014-02-14.
Discontinued › Notes
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2014-02-14
- 2013-12-31: Long-Term Debt, Maturity, after Year Five $5.50B.
- 2012-12-31: Long-Term Debt, Maturity, after Year Five $4.55B.
- 2011-12-31: Long-Term Debt, Maturity, after Year Five $3.42B.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2013-12-31 | $5.50B 10-K · filed 2014-02-14 |
| 2012-12-31 | $4.55B 10-K · filed 2013-02-15 |
| 2011-12-31 | $3.42B 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |